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Prions are unconventional infectious agents responsible for transmissible spongiform encephalopathies. Compelling evidences indicate that
prions are composed exclusively by a misfolded form of the prion protein (PrPSc) that replicates in the absence of nucleic acids. One of the most
challenging problems for the prion hypothesis is the existence of different strains of the infectious agent. Prion strains have been characterized in
most of the species. Biochemical characteristics of PrPSc used to identify each strain include glycosylation profile, electrophoretic mobility,
protease resistance, and sedimentation. In vivo, prion strains can be differentiated by the clinical signs, incubation period after inoculation and the
lesion profiles in the brain of affected animals. Sources of prion strain diversity are the inherent conformational flexibility of the prion protein, the
presence of PrP polymorphisms and inter-species transmissibility. The existence of the strain phenomenon is not only a scientific challenge, but it
also represents a serious risk for public health. The dynamic nature and inter-relations between strains and the potential for the generation of a
large number of new prion strains is the perfect recipe for the emergence of extremely dangerous new infectious agents.
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Transmissible Spongiform Encephalopathies (TSEs), also
known as prion disorders, are infectious and fatal neurodegenerative
diseases affecting humans and other mammals. In humans, TSEs
include Creutzfeldt–Jakob disease (CJD), fatal familial insom-
nia (FFI), Gertsmann–Straussler–Scheinker Syndrome (GSS)
and Kuru [1,2]. In other mammals, bovine spongiform
encephalopathy (BSE) is found in cattle, scrapie in sheep and
goats and chronic wasting disease (CWD) in elk and deer [1,2].
Although the clinical symptoms vary in distinct diseases, they
usually include dementia and/or ataxia with progressive loss of
brain function, irreversibly resulting in death [3]. The hallmark
of prion diseases is the misfolding of the prion protein observed
in the brain of affected individuals [1]. Misfolded proteins have
the intrinsic tendency to form large aggregates and fibrillar
structures, that may form amyloid deposits in a similar fashion as⁎ Corresponding author.
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doi:10.1016/j.bbadis.2006.12.006observed in Alzheimer's, Parkinson's diseases and many other
protein misfolding disorders [4].
Although of rare occurrence, prion diseases have drawn
considerable attention and led to severe economic and political
consequences in Europe and in the United States. The two main
reasons of this impact include the unique nature of the infectious
agent and the appearance of a new human disease (vCJD) linked
to consumption of cattle meat infected by BSE. At present, it is
impossible to estimate accurately the number of upcoming cases
of vCJD due to the very long incubation time of the disease in
humans [5–7]. Prion research has been plagued with the
discovery of new and heretic scientific findings that have
confronted the most solid paradigms in modern biology. The
current evidence suggest that an abnormal form of the prion
protein (termed PrPSc) is the main, and possibly the only,
constituent of prion infectious agent [1]. This so-called protein-
only hypothesis [1,8] proposes that replication of PrPSc occurs
at expenses of the normal host's version of the prion protein
(termed PrPC). PrPSc has different biochemical characteristics
compared to PrPC, for example its insolubility, resistance to
denaturation, and its partial resistance to protease degradation
Fig. 1. PrPSc western blot profiles associated to different strains of human prions.
Schematic representation of human PrPSc types after PK digestion. Particular
polymorphic groups in position 129 are associated with specific PrPSc patterns.
Types 1 and 2 are associated with sCJD, type 3 is mostly associated with iCJD
and type 4 is found exclusively in vCJD.
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core of the infectious agent (termed PrP27–30 according to its
molecular weight) [10].
2. Molecular basis of prion strains
Among the unique features that have contributed to place the
prion field in the spotlight, one of the most interesting is the
prion strain phenomenon. It has been observed that animals
affected by prion diseases may develop different pathologies
and the clinical and biochemical outcomes could be maintained
through several passages in rodents models of prion diseases. In
analogy to other infectious agents, these variants have been
termed strains. A classical definition of strain makes mention to
a genetic variant or subtype of the infectious agent responsible
for the disease, but this concept, valid in virology, cannot be
extended to prions. In early days, the strain phenomenon was
claimed as one of the strongest evidences against the protein-
only hypothesis [11,12]. It was assumed that the different
phenotypes found in animals were due to differences in the
genetic information contained within the TSE causing agent.
However, currently it is widely accepted that the main
differences between prion strains arise from alternative
conformations of PrPSc that can be stably and faithfully
propagated [13,14].
The first evidence about the existence of prion strains was
described in goats affected by scrapie by Pattison and Millson in
1961 [15]. In this report, goats infected by the same batch of
infectious scrapie agent developed two different clinical
phenotypes, termed by the authors “scratching” and “drowsy”,
according to disease's manifestation. The differences between
these infectious agents were alleged to be the consequence of
differences in the genetic background of the host. The current
evidence supports this hypothesis. In some cases, clinical signs
could be very useful to differentiate between prion strains [15–
17]. Each prion strain has the capability to affect specific brain
areas producing differences in clinical signs. In the case of
scrapie in sheep and goats, after identification and isolation of
the prion protein gene (prnp) several polymorphic differences
were recognized when numerous sheep flocks were compared
[18].
Prion strains can be classified by different parameters.
Incubation periods, profile of histological damage and clinical
signs are the main in vivo characteristics which can be used to
differentiate between prion strains [16,19,20]. The most
commonly used is incubation period which corresponds to the
time elapsed between experimental inoculation of the infectious
agent and clinical onset of the disease. Intra-species inoculation
of prions is usually very reproducible [19]. Inoculation of
different prion strains preparations usually results in different
and reproducible incubation times [19,21]. Histological studies
have also shown substantial differences when animals were
inoculated with distinct strains. The differences are mainly on
the distribution and characteristics of PrPSc deposition and the
degree of vacuolation in specific brain regions [22–25]. In order
to quantify this aspect, a well-standardized procedure for
vacuolization scoring (lesion profile) in mice [25] has beendescribed; six gray matter and three white matter brain areas are
analyzed and scored according to the magnitude of the damage.
Using this approach, prion strains having similar incubation
times were differentiated, such as ME7 and 79A [25]. In a
similar way, PrPSc accumulation profile has been useful to track
the origin of the infectious material. For example, in the case of
the transmission of BSE into humans, originating vCJD, similar
neuropathological signatures were produce [26,27]. Finally, the
clinical signs are also a characteristic that can be very useful to
differentiate strains. For example, in human prion diseases,
motor incoordination, dementia, ataxia, depression, and insom-
nia are just few from a much larger list of clinical symptoms that
can appear with more or less intensity depending on the strain of
the agent [3]. In other animals, such as the case of hamsters, the
clinical features can be diametrically opposed. That is the case
of the Drowsy (DY) and Hyper (HY) prion strains [16].
Unfortunately, clinical signs cannot always be applied to
differentiate and classify prion strains. In mouse for example,
several prion strains have the same rough signs, which include
ataxia, rough coat, and hunch [28,29]. However, studies using
more detailed tests have identified dissimilar behavioral deficits
when different prion strains are administrated to mice [30].
Since different brain lesion patterns appear to be responsible for
the variation in clinical signs, behavioral studies could give us
more specific information about the type of brain damage
produced by different prion isolates [30,31].
In addition to the in vivo differences, each prion strain has a
particular group of biochemical characteristics in the infectious
protein that could be specifically associated to them. Among
them, the most important are the electrophoretical mobility after
proteinase K (PK) digestion [32–34], glycosylation pattern
[33–35], extent of PK resistance [32], sedimentation [32] and
resistance to denaturation by chaotropic agents [32,36].
Recently, differences in the binding affinity for copper among
strains have been described [37]. As illustrated in Fig. 1, the
biochemical features of PrPSc in various forms of CJD are
different. The western blot profile of different sources of human
PrPSc shows diversity in terms of glycosylation pattern and
electrophoretical mobility after PK digestion [32–34]. Fourier
Transform Infrared Spectroscopy (FTIR) studies involving
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immunoassays [36,40] and atomic force microscopy of
synthetic prion protein polymers [41] confirm the hypothesis
that differences between prion strains lies in the diversity of
structures that PrPSc can acquire. However, the definitive proof
for the structural nature of the differences between prion strains
is still missing.
3. Species barrier and generation of new prion strains
The principal source of strain diversity arise from inter-
species infection [23,42–45]. One of the characteristics of the
agent responsible for prion diseases is its ability to infect some
species and not others. This phenomenon is known as “species
barrier” and is manifested as the prolongation in the incubation
periods when prions from one species are used to infect a
different one [46,47]. Differences in the sequence of prion
protein could lead to different conformations, explaining both,
species barrier and diversity of PrPSc conformations [41,48–
50]. In some species, PrPC conformation does not permit
conversion by prions coming from other species. A clear
example of this is found in rabbit, an animal that has been
unable to be infected by various sources of prions. In these
cases, it is considered that the species barrier is absolute.
Interspecies prion transmission from cattle to human is
probably the most relevant problem in terms of public health
[51–53]. It is widely accepted that consumption of BSE infected
material is the cause of vCJD in humans [27,54]. Strikingly,
vCJD presents many different features compared to the
previously known human strains, arisen sporadically. Differ-
ences between vCJD and sCJD include the clinical manifesta-
tion of the disease, the profile of brain damage and the
biochemical features of PrPSc [55]. The BSE epidemic in the
United Kingdom demonstrated how dangerous prions could be.
So far, BSE is the only non-human prion described to be
transmissible to humans. Despite the fact that people have
consumed for centuries sheep potentially affected by scrapie, no
correlation has been found between patients suffering by CJD
and sheep consumption. Scrapie transmissibility experiments
using transgenic animal models expressing chimeric human/
mouse PrP support this assumption [56].
BSE has not only been transmitted to humans. The extensive
use of cow-derived material for feeding other animals led to the
generation of new diseases in exotic felines such as tiger and
cheetah, non human primates, and domestic cats [52,57–60].
The transmission of BSE into these different species could
create many new prion strains, each one of them with particular
biological and biochemical characteristics and thus a potentially
new hazard for human health. Successful transmission of BSE
in pigs has been described [61,62] and also in transgenic mice
expressing pig PrP [63]. Porcine derivates are widely consumed
and the hypothetic case of “mad pigs” could increase the events
of zoonotic transmission of prions to humans. Fortunately,
transmission of BSE to pigs is possible only in very drastic
experimental conditions, not likely to be occurring naturally
[62,63]. More frightening is perhaps the possibility that BSE
has been passed into sheep and goats. Studies have alreadyshown that this transmission is possible and actually relatively
easy and worrisomely produces a disease clinically similar to
scrapie [64]. The cattle origin of this new scrapie makes
possible that the new strain may be transmissible to humans.
Transmission experiments of BSE infected sheep brain homo-
genate into transgenic animal models expressing human PrP are
currently ongoing in several laboratories. It is important to note
that all materials generated by transmission of BSE in
experimental and natural cases show similar biochemical
behavior compared to the original inoculum [65], suggesting
that these new generated infectious agents might be hazardous
for humans. The origin of BSE is still a mystery. Abundant
evidence supports the hypothesis that BSE was produced by
cattle feeding with scrapie derivated material [66,67], indicating
that bovine PrPSc might be a “conformational intermediary”
between ovine PrPSc and human PrPC.
There is currently no mean to predict which will be the
conformation of a newly generated strain and how this new
PrPSc conformation could affect other species. One interesting
new prion disease is CWD, a disease affecting farm and wild
species of cervids [68,69]. The origin of CWD and its potential
to transmit to humans are currently unknown. This is
worrisome, considering that CWD has became endemic in
some parts of USA and the number of cases continues to
increase [69]. It is presumed that a large number of hunters in
the US have been in contact or consumed CWD-infected meat
[70]. CWD transmissibility studies have been performed in
many species in order to predict how this disease could be
spread by consumption of CWD meat [71–73]. In these studies,
a special attention has been done to scavenging animals [74],
which are presumed to be exposed to high concentration of
cervid prions, resulting in the putative generation of many new
forms of TSEs. Fortunately negative results were obtained in
experiments done in raccoons infected with CWD [74].
Transmission of CWD to humans cannot be ruled out at present
and a similar infective episode to BSE involving CWD could
result in catastrophic events, spreading the disease in a very
dangerous way through the human population. No clinical
evidence linking CWD exposed humans and CJD patients have
been found [70], but experimental inoculation of CWD prions
into squirrel monkeys propagated the disease [71]. Never-
theless, the species barrier between humans and cervids appears
to be greater than with cattle, as judged by experiments with
transgenic mice models [75]. Finally, it is important to be aware
about CWD transmissibility to other species in which a
“conformational intermediary” could be formed, facilitating
human infection.
4. Use of experimental animals to study prion strains
Probably the best way to study the strain phenomenon is
using experimental animals for the generation of diverse strains
through inoculation with prion infectious material coming from
different species. Among the experimental models, perhaps
mouse is the most useful one, in which more than 20
phenotypically distinct strains have been isolated [19]. Many
of these strains have their origin in the transmission of different
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from cattle [23,24,76] and human sources as sCJD and GSS
[44,77,78]. Serial passage of infectious prions in one species,
with constant biological background is necessary to stabilize
and define a prion strain.
PrPSc obtained from mouse adapted scrapie prion strains
such as RML, ME7, 139A and 79A show similar electro-
phoretical characteristics after PK digestion. PrPSc coming from
these strains show an electrophoretical mobility of ∼21 kDa for
the unglycosylated band and a similar glycosylation pattern,
with the monoglycosylated form as the most abundant [79–83].
Despite the lack of biochemical differences, these strains can be
differentiated when inoculated in mice by measuring the
incubation time or the profile of brain lesions [25,28,82,84].
Other mouse strains have been generated by inoculation of
animals with BSE and sCJD prions, leading to strains termedFig. 2. Origin and properties of the HY and DY prion strains in hamsters. The Hype
transmissible mink encephalopathy (TME) infectious material in Syrian hamsters.
successive passage stabilized in two different strains exhibiting strikingly different cli
hamster strains represent a prototype example of strain diversity without changes in301C and Fukuoka, respectively [42,43,85]. The transmission
of BSE into mice generated two different phenotypes: one
presenting PK resistant isoform of PrPSc, and another lacking
this characteristic [76]. This phenotype is maintained after two
serial passages in mice, but finally only the PK resistance
phenotype remains. The presence of a PK sensitive infectious
material (termed sPrPSc) has been also described in some cases
of human prion diseases [86,87].
The characteristics of mouse strains generated from scrapie
or from BSE are quite different. For example, intracerebral
inoculation of RML strain into mice present an onset of
∼150 days post inoculation (dpi), while 301C preparations
cause the disease at ∼200 dpi [19,88]. Intraperitoneal
inoculation of RML and 301C material in the same animals
shows a larger difference in the incubation periods: 200 and
300 dpi, respectively [24,84]. There are also differences in ther (HY) and Drowsy (DY) scrapie strains were generated upon serial passage of
The initial passage resulted in a very large incubation period that was upon
nical, neuropathological, biochemical and infectious properties. The HYand DY
amino acid sequence of the prion protein.
Table 1
Polymorphisms associated to prion diversity in mouse
Mouse prnp
genotype
Mouse strain Prion strains Associated
polymorphisms









The table shows different mouse strain and prion strains isolated in each
polymorphic group.
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Morales R., Saá P., and Soto C.; unpublished data). In
addition, it is also possible to find biochemical differences
between RML and 301C strains. As mentioned above, PK
digestion pattern of RML shows an electrophoretical mobility
of ∼21 kDa for the unglycosylated band and is rich in the
monoglycosylated isoform of prion protein. In contrast, 301C
prion strain show a different electrophoretical pattern com-
pared to RML. Unglycosylated isoform of BSE adapted
mouse strain shows an electrophoretical mobility of ∼19 kDa
and its glycoform distribution favors the diglycosylated
isoform [83].
How different PrPSc conformations could induce stable
conformational changes in the same host protein is still
unknown. Even more interesting is the isolation of different
prion strains from the same host after inoculation of PrPSc from
a single species. Probably the most representative experience is
the isolation of DYand HY strains after inoculation of the agent
associated to transmissible mink encephalopathy (TME) in
Syrian hamsters (Fig. 2) [13,16]. This interspecies transmission
of prions presented the expected behavior of the species barrier
phenomenon: a long incubation period in the first passage, but
shorter incubation periods after inoculation of serial passages
from the resulting infectious material into Syrian hamsters.
Incubation periods became stable in two different groups with
different clinical signs: the first one with an incubation period
of ∼150 dpi presented lethargy, while a shorter incubation
period strain (∼60 dpi) presented hyperactivity. These strains
were called Drowsy (DY) and Hyper (HY) respectively
according to their clinical signs [16]. Histopathological analysis
of animal groups infected with both TME hamster adapted
agents show differences in the vacuolation distribution among
different brain regions [16] and also in the PrPSc deposition
areas [89] (Fig. 2).
As 301C and RML in mouse, DYand HYpresent differences
in their electrophoretical mobility after PK treatment. The
unglycosylated band of DY has a molecular weight of 19 kDa,
while HY show the same band at 21 kDa [32,90]. This is the
most direct evidence that suggested conformational differences
between both PrPSc species. Supporting this assumption,
structural differences using Fourier transform infrared spectro-
scopy (FTIR) between both Syrian hamster adapted TME
strains were found [38]. Another biochemical difference found
between DY and HY lies in their differential resistance to PK
digestion, where DY is the most sensitive to digestion compared
to HY [32] (Fig. 2). All these biological and biochemical
characteristics make DY and HY one of the most intriguing
examples of prion strain variation.
5. Polymorphisms and prion strains
Polymorphisms in the prion protein and their effects in the
prion strain phenomenon were indirectly described a long time
before the prion hypothesis was developed [15]. Differences in
prion pathology were found and extensively described in sheep
and mice [17–19,25]. The drowsy and scratchy phenotypes
found in sheep were attributed to polymorphic differences in thehost [17]. The identification of “scrapie incubation period gene”
(sinc) and its polymorphic differences was a very big hit in the
study of prion strains [91]. In mouse, two polymorphic animal
groups were originally described: sincs7 and sincp7. Later, it
was discovered that the sinc gene was indeed the gene encoding
PrP and the polymorphisms resulted in differences in the prion
protein at positions 108 and 189 [92]. The transmission of
infectious agents from sheep, goats and cattle to both mice
groups resulted in the emergence of a wide diversity of prion
strains [19,28]. When incubation periods of mouse adapted
prions were stabilized in each group, new generated infectious
agent could be assayed in the other animal group. It was found
that the presence of the polymorphism produced a prolongation
in the incubation period in a similar way as observed in the
species barrier phenomenon [19]. It was postulated that prion
strains in mouse could be differentiated inoculating infectious
material in both animals' types and identifying the short and
long incubation period animal cluster [19]. Interestingly, when a
mouse prion strain is inoculated in sinc heterozygous animals,
either intermediate or longer incubation periods are observed
[28]. Inter-polymorphic transmissions can lead to the generation
of new prion strains [19], which implies new vacuolation,
infectivity and/or dominance characteristics, among others. All
this information suggests that polymorphisms in the prion
protein are able to favor strain diversity. Table 1 shows mice and
prion strains corresponding to each polymorphic group.
After the isolation of prion protein gene [93], it was
described that sinc and prnp genes were congruent [94].
Analysis of long and short incubation period animal groups
revealed the expected polymorphic differences in the prion
protein gene [21]. These findings strongly supports the prion
hypothesis, because as observed in the species barrier
phenomenon, differences in the sequence of the prion protein
affect extensively the transmission and strain characteristics of
the infectious agent. According to a new nomenclature
generated, sincs7 animals are re-baptized as prnpa, while
sincp7 as prnpb [21]. Recently a new group of mice have been
identified and named prnpc (Table 1) [88].
PrP polymorphisms are not unique of mouse. Indeed,
polymorphisms in the prion protein have been described in
most of the species. In sheep, several inter-bred crosses have
been performed in order to optimize the quality and productivity
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variants for prnp [18]. However, only five alleles of the PrP
gene are significantly present giving a total of 15 possible PrP
genotypes, each likely to favor or disfavor the selection of
different scrapie strains [18]. These five common polymorphic
alleles are ARQ, ARR, AHQ, ARH and VRQ. Polymorphic
changes are present principally in codons 136, 154 and 171, but
in order to simplify the nomenclature they are designated by the
amino acid present in each position. In a recent revision by
Baylis and Goldman [18] it is documented that sheep carrying
the VRQ/VRQ, ARH/VRQ and ARQ/VRQ alleles are most
susceptible to develop scrapie, whereas the less vulnerable are
animals having ARR/ARR, ARR/ARH and AHQ/ARH alleles.
Therefore, it is generally agreed that the VRQ allele promotes
susceptibility to scrapie, whereas ARR diminishes the mani-
festation of the disease. Interestingly, other alleles such as ARH
alone appear to favor the development of the disease while in
combination with other alleles appear to confer resistance. In the
same study, a correlation was established between incubation
periods and the type of polymorphism. A linear relationship
between age of death and five polymorphic groups was
observed. Many prion strains have been described for scrapie.
Each strain is associated to a particular allelic group, and allelic
groups are associated to a particular breed of animals [42,95].
However, as previously described, prion protein diversity could
exist with the same sequence in the prion protein and sheep is
not the exception. CH1641, a prion strain with clear
biochemical differences compared to other scrapie strains was
isolated from a natural case of scrapie in Cheviot sheep [96].
Recently a new scrapie strain designated Nor98 has been
described [95], mostly in animals having AHQ/AHQ and AHQ/
ARQ genotypes (a variation relatively resistant to scrapie). In
this case, “classically susceptible” alleles seem to be resistant to
this class of prions [18,97]. All this information arise questions
about how natural cases of scrapie are developed.
In humans there is a polymorphism at codon 129, where an
ATG or GTG results in either a methionine (Met) or a valine
(Val) at that position. A large body of evidence indicates that
this polymorphism alone or in conjunction with mutations in the
prion gene modulates disease susceptibility and phenotypic
expression of human TSE [2,34,98–104]. Both Met and Val
homozygous are over-represented, while heterozygous cases are
under-represented in sCJD [98,99,105]. About 40% of the
normal population is Met-homozygous, however 78%, 50% and
100% of patients affected by the sporadic, iatrogenic and variant
forms of CJD are Met-homozygous, respectively [105–109].
These data suggest that the presence of Met at position 129
confers a higher susceptibility for the protein to be converted
into the pathogenic isoform. The polymorphism has also been
shown to alter the neuropathological pattern of lesions in
sporadic CJD, the glycoform profile of protease-resistant PrPSc
and the duration and severity of the disease [34,102,103,110–
113]. A study involving 300 patients showed that Met-
homozygous develop a more aggressive phenotype character-
ized by a short duration of disease (4.5 months), while
heterozygous and Val-homozygous have a much longer disease
duration (14.3 and 16.9 months, respectively) [103]. Val-homozygous seems to cause damage preferentially in the deep
gray matter, while Met-homozygous seems to target mainly
cortical structures [103]. Codon 129 polymorphism also
influences the phenotypic expression of mutations elsewhere
in the prion gene [104,114–119]. For example, people with a
mutation at codon 178 resulting in a change of aspartic acid to
asparagine develop either familial CJD or FFI depending on
whether the amino acid at codon 129 is Val or Met, respectively
[104].
Despite the clear importance of PrP polymorphism at
position 129 in the disease propensity and pathogenesis, the
molecular mechanism of this effect is unknown. Experimental
and computational modeling studies of the tridimensional
structure of PrP have been unable to identify any significant
difference between the two isoforms [120]. In addition, no
difference was reported on the in vitro thermodynamic stability
of recombinant PrP bearing either Met or Val at position 129
[120,121]. Structural studies show evidence for hydrogen
bonding between Asp178 and Tyr128, which might provide a
structural basis for the influence of the polymorphism on the
disease phenotype that segregates with the mutation
Asp178Asn [121]. In addition, it has been reported that a
slightly different conformation of recombinant Met- or Val-
containing PrP isoforms was induced upon copper binding
[122]. Using short model peptides, we found that M at position
129 increases the propensity of this region to aggregate into β-
sheet rich fibrillar structures [123]. These findings were
interpreted to suggest that Met induces a higher local propensity
to extend the short β-sheet present in the normal protein into a
larger sheet, which results in an increase in the rate of PrP
conversion to the pathological isoform [123].
6. Unique features of prion strains
The biological and infectious characteristics of prions are
dramatically different to the conventional infectious agents.
These differences are manifested in the prion strains phenom-
enon in unique and unprecedented features, such as for example
strain adaptation and memory, the coexistence and competition
of prion strains, among others. In this section, some of these
interesting phenomena will be briefly described.
6.1. Adaptation of prion strains
Interspecies transmission of prions could result in the
emergence of more than one variety of infectious material
with different strain characteristics. That is the case of DY and
HY prion strains generation [13,16]. When interspecies
transmission of prions occurs, serial passages in the new host
are needed in order to stabilize the characteristics of new
generated infectious material. In the case of TME transmission
in hamsters, at least four serial passages in the new species were
required for stabilization (Fig. 2) [13]. The first passage was
characterized by long incubation periods and a dominance of a
19 kDa fragment when newly obtained PrPSc was analyzed after
PK digestion. In the three first passages, clinical symptoms were
not characteristic of the hamster-adapted HY or DY TME
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effects of both strains replicating simultaneously. Thereafter,
each of the strains was stabilized in some of the animals and
once they are adapted and stabilized, they can be serially
propagated in vivo and the characteristics are maintained. It is
accepted that both strains present differential conversion
kinetics in vitro, with DY being the slowest and HY the fastest
[124]. For this reason, in order to select efficiently this prion
strain, limiting dilution experiments must be performed [13]. In
that way, the most abundant and less convertible DY is favored
against the less abundant but fastest HY strain.
6.2. Co-existence of prion strains
Related to the above, it has been shown that two or more
prion strains can co-exist in natural cases of TSE. Co-existence
of prion strains has been found in sporadic cases of CJD
[113,125]. Analyses of several sCJD tissue showed that
different biochemical profiles of PrPSc could be found in
different brain areas from the same patient [113]. Co-existence
of prion strains was mainly observed in patient heterozygous for
codon 129 [113]. As many as 50% of these patients present
different types of PrPSc in their brains, whereas 9% of MM
patients were positive for co-existence of strains. On the other
hand, more than one PrPSc type was not observed in VV
patients [113].
The biochemical and structural properties of the protein seem
to be the major cause of this differential distribution. This
observation may explain why sCJD is so heterogeneous in terms
of clinical manifestation [34,126,127]. In a recent publication
by Bishop et al. [107], vCJD infected transgenic mice
expressing human PrPC, present changes in their PrPSc and
vacuolation patterns in the brain according to their polymorphic
classification for codon 129.
6.3. Competition of prion strains
In particular experimental conditions some prion strains can
extend their specific incubation period when co-infected with
another strain. Long incubation period prions increase the
incubation period of “faster” prions. This phenomenon of
“competition of prion strains” has been observed in mice and
hamster. In mice, competition between 22A and 22C strains was
reported in 1975 by Dickinson et al. [128]. In this study, RIII
mice (homozygous for sincs7 allele) were used. 22A and 22C
showed long and short incubation period (550 and 230 days),
respectively. When 22C strain was intraperitoneally inoculated
100, 200 and 300 days after intraperitoneal administration of the
22A agent, all three experimental groups resulted in incubation
periods and lesion patterns matching 22A prions, suggesting that
22C prions were degraded or excreted, in animals previously
infected by 22A. Similar results were obtained by Kimberlin and
Walker in 1985 [129] using a different strain of sincs7 mice.
These authors treated mice using 22A and 22C prion strain.
Before inoculation, 22Awas treated with different chemical and
physical agents in order to see if the “competitor” or “blocking”
characteristics of 22A were maintained. From all treatments,12 M urea was shown to almost abolish the blocking properties
of 22A agent. This information suggests that infectious proper-
ties of long incubation period agent are strictly necessary in order
to increase the incubation period of faster prions.
In hamster, similar observations were reported using DYand
HY [130]. DY prion strain was inoculated 30 and 60 days prior
intraperitoneal inoculation of HYat three different doses. When
incubation periods of HY inoculated control group were
compared with the animals inoculated at 60 days with DY,
significant differences in the incubation periods were found,
especially when HY prions were administrated in a higher dose
[130]. On the other hand no differences were observed in the
case of intranerve inoculation, revealing that competition
phenomenon occurs only when peripheral inoculation is
performed. These results are surprising considering the fact
that DY was reported not to be infectious when intraperitoneally
inoculated in hamsters [130]. These data suggest that replication
of DY is occurring in peripheral tissues but is not able to reach
the central nervous system.
In general, the principal variables that need to be observed
for a successful competition are the route of infection, the
interval between injections and the particular strains and doses
of agent used. Prolongation of incubation periods in TSE are
therapeutically beneficial and several strategies are under
development to reach this aim, including antibodies, beta-
sheet breakers, and other chemical agents [131–133]. The
experimental evidence described above suggests that prions
could be potentially useful for this purpose. For example, in
order to prevent spread of prion disease in cattle or humans,
prion strains with incubation periods longer than species'
lifespan could be used to slowdown the replication of BSE or
vCJD prions.
7. Concluding remarks
The existence of different strains of an infectious agent
composed exclusively of a protein has been one of the most
puzzling issues in the prion field. If is already difficult to
understand how a protein can adopt two stable and different
folded structures and that one of them can transform the other
one into itself, it is unthinkable that the misfolded form can in
turn adopt multiple conformations with distinct properties. Yet,
compelling scientific evidence support the idea that PrP can
adopt numerous folding patterns that can faithfully replicate and
produce different diseases. The existence of the strain
phenomenon is not only a scientific challenge, but it also
represents a serious risk for public health. The dynamic nature
and inter-relations between strains and the potential for the
generation of many new prion strains depending on the
polymorphisms and the crossing of species barrier is the perfect
recipe for the emergence of extremely dangerous new infectious
agents. Although, substantial progress has been made in
understanding the prion strains phenomenon, there are many
open questions that need urgent answers, including: what are the
structural basis of prion strains? How are the phenomena of
strain adaptation and memory enciphered in the conformation of
the prion agent? To what species can a given prion strain be
688 R. Morales et al. / Biochimica et Biophysica Acta 1772 (2007) 681–691transmissible? What other cellular factors control the origin and
properties of prion strains?
Acknowledgement
This research was supported in part by NIH grant NS049173.
References
[1] S.B. Prusiner, Prions, Proc. Natl. Acad. Sci. U. S. A. 95 (1998)
13363–13383.
[2] J. Collinge, Prion diseases of humans and animals: their causes and
molecular basis, Annu. Rev. Neurosci. 24 (2001) 519–550.
[3] H. Budka, A. Aguzzi, P. Brown, J.M. Brucher, O. Bugiani, F. Gullotta, M.
Haltia, J.J. Hauw, J.W. Ironside, K. Jellinger, Neuropathological
diagnostic criteria for Creutzfeldt–Jakob disease (CJD) and other
human spongiform encephalopathies (prion diseases), Brain Pathol. 5
(1995) 459–466.
[4] C. Soto, Unfolding the role of protein misfolding in neurodegenerative
diseases, Nat. Rev., Neurosci. 4 (2003) 49–60.
[5] C.H. Cohen, A.J. Valleron, When did bovine spongiform encephalopathy
(BSE) start? Implications on the prediction of a new variant of
Creutzfeldt–Jakob disease (nvCJD) epidemic, Int. J. Epidemiol. 28
(1999) 526–531.
[6] A.C. Ghani, N.M. Ferguson, C.A. Donnelly, T.J. Hagenaars, R.M.
Anderson, Estimation of the number of people incubating variant CJD,
Lancet 352 (1998) 1353–1354.
[7] R. Will, Variant Creutzfeldt–Jakob disease, Folia Neuropathol. 42 (2004)
77–83 (Suppl A).
[8] J.S. Griffith, Self-replication and scrapie, Nature 215 (1967) 1043–1044.
[9] F.E. Cohen, S.B. Prusiner, Pathologic conformations of prion proteins,
Annu. Rev. Biochem. 67 (1998) 793–819.
[10] S.B. Prusiner, D.F. Groth, D.C. Bolton, S.B. Kent, L.E. Hood,
Purification and structural studies of a major scrapie prion protein, Cell
38 (1984) 127–134.
[11] B. Chesebro, BSE and prions: uncertainties about the agent, Science 279
(1998) 42–43.
[12] C. Soto, J. Castilla, The controversial protein-only hypothesis of prion
propagation, Nat. Med. 10 (2004) S63–S67.
[13] J.C. Bartz, R.A. Bessen, D. McKenzie, R.F. Marsh, J.M. Aiken,
Adaptation and selection of prion protein strain conformations following
interspecies transmission of transmissible mink encephalopathy, J. Virol.
74 (2000) 5542–5547.
[14] D. Peretz, M.R. Scott, D. Groth, R.A. Williamson, D.R. Burton, F.E.
Cohen, S.B. Prusiner, Strain-specified relative conformational stability of
the scrapie prion protein, Protein Sci. 10 (2001) 854–863.
[15] I.H. Pattison, G.C. Millson, Scrapie produced experimentally in goats
with special reference to the clinical syndrome, J. Comp. Pathol. 71
(1961) 101–109.
[16] R.A. Bessen, R.F. Marsh, Identification of two biologically distinct
strains of transmissible mink encephalopathy in hamsters, J. Gen. Virol.
73 (Pt 2) (1992) 329–334.
[17] A.G. Dickinson, Scrapie in sheep and goats, Front Biol. 44 (1976)
209–241.
[18] M. Baylis, W. Goldmann, The genetics of scrapie in sheep and goats,
Curr. Mol. Med. 4 (2004) 385–396.
[19] M.E. Bruce, Scrapie strain variation and mutation, Br. Med. Bull. 49
(1993) 822–838.
[20] H. Fraser, Diversity in the neuropathology of scrapie-like diseases in
animals, Br. Med. Bull. 49 (1993) 792–809.
[21] D. Westaway, P.A. Goodman, C.A. Mirenda, M.P. McKinley, G.A.
Carlson, S.B. Prusiner, Distinct prion proteins in short and long scrapie
incubation period mice, Cell 51 (1987) 651–662.
[22] M.E. Bruce, P.A. McBride, C.F. Farquhar, Precise targeting of the
pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in
mouse scrapie, Neurosci. Lett. 102 (1989) 1–6.[23] M.E. Bruce, A. Boyle, S. Cousens, I. McConnell, J. Foster, W.
Goldmann, H. Fraser, Strain characterization of natural sheep scrapie
and comparison with BSE, J. Gen. Virol. 83 (2002) 695–704.
[24] C.I. Lasmezas, J.P. Deslys, R. Demaimay, K.T. Adjou, J.J. Hauw, D.
Dormont, Strain specific and common pathogenic events in murine
models of scrapie and bovine spongiform encephalopathy, J. Gen. Virol.
77 (1996) 1601–1609.
[25] H. Fraser, A.G. Dickinson, Scrapie in mice. Agent-strain differences in
the distribution and intensity of grey matter vacuolation, J. Comp. Pathol.
83 (1973) 29–40.
[26] M.R. Scott, R. Will, J. Ironside, H.O. Nguyen, P. Tremblay, S.J.
DeArmond, S.B. Prusiner, Compelling transgenetic evidence for
transmission of bovine spongiform encephalopathy prions to humans,
Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 15137–15142.
[27] M.E. Bruce, R.G. Will, J.W. Ironside, I. McConnell, D. Drummond,
A. Suttie, L. McCardle, A. Chree, J. Hope, C. Birkett, S. Cousens, H.
Fraser, C.J. Bostock, Transmissions to mice indicate that ‘new
variant’ CJD is caused by the BSE agent, Nature 389 (1997)
498–501.
[28] M.E. Bruce, I. McConnell, H. Fraser, A.G. Dickinson, The disease
characteristics of different strains of scrapie in Sinc congenic mouse lines:
implications for the nature of the agent and host control of pathogenesis,
J. Gen. Virol. 72 (1991) 595–603.
[29] A.G. Dickinson, V.M. Meikle, H. Fraser, Identification of a gene which
controls the incubation period of some strains of scrapie agent in mice, J.
Comp. Pathol. 78 (1968) 293–299.
[30] G. Dell'Omo, E. Vannoni, A.L. Vyssotski, M.A. Di Bari, R. Nonno, U.
Agrimi, H.P. Lipp, Early behavioural changes in mice infected with BSE
and scrapie: automated home cage monitoring reveals prion strain
differences, Eur. J. Neurosci. 16 (2002) 735–742.
[31] C. Cunningham, R.M. Deacon, K. Chan, D. Boche, J.N. Rawlins, V.H.
Perry, Neuropathologically distinct prion strains give rise to similar
temporal profiles of behavioral deficits, Neurobiol. Dis. 18 (2005)
258–269.
[32] R.A. Bessen, R.F. Marsh, Biochemical and physical properties of the
prion protein from two strains of the transmissible mink encephalopathy
agent, J. Virol. 66 (1992) 2096–2101.
[33] J. Collinge, K.C. Sidle, J. Meads, J. Ironside, A.F. Hill, Molecular
analysis of prion strain variation and the aetiology of ‘new variant’ CJD,
Nature 383 (1996) 685–690.
[34] P. Parchi, R. Castellani, S. Capellari, B. Ghetti, K. Young, S.G. Chen, M.
Farlow, D.W. Dickson, A.A. Sima, J.Q. Trojanowski, R.B. Petersen, P.
Gambetti, Molecular basis of phenotypic variability in sporadic
Creutzfeldt–Jakob disease, Ann. Neurol. 39 (1996) 767–778.
[35] A. Khalili-Shirazi, L. Summers, J. Linehan, G. Mallinson, D. Anstee, S.
Hawke, G.S. Jackson, J. Collinge, PrP glycoforms are associated in a
strain-specific ratio in native PrPSc, J. Gen. Virol. 86 (2005) 2635–2644.
[36] J. Safar, H. Wille, V. Itri, D. Groth, H. Serban, M. Torchia, F.E. Cohen, S.
B. Prusiner, Eight prion strains have PrP(Sc) molecules with different
conformations, Nat. Med. 4 (1998) 1157–1165.
[37] J.D. Wadsworth, A.F. Hill, S. Joiner, G.S. Jackson, A.R. Clarke, J.
Collinge, Strain-specific prion-protein conformation determined by metal
ions, Nat. Cell Biol. 1 (1999) 55–59.
[38] B. Caughey, G.J. Raymond, R.A. Bessen, Strain-dependent differences in
beta-sheet conformations of abnormal prion protein, J. Biol. Chem. 273
(1998) 32230–32235.
[39] P. Aucouturier, R.J. Kascsak, B. Frangione, T. Wisniewski, Biochemical
and conformational variability of human prion strains in sporadic
Creutzfeldt–Jakob disease, Neurosci. Lett. 274 (1999) 33–36.
[40] A. Bellon, W. Seyfert-Brandt, W. Lang, H. Baron, A. Groner, M. Vey,
Improved conformation-dependent immunoassay: suitability for human
prion detection with enhanced sensitivity, J. Gen. Virol. 84 (2003)
1921–1925.
[41] E.M. Jones, W.K. Surewicz, Fibril conformation as the basis of species-
and strain-dependent seeding specificity of mammalian prion amyloids,
Cell 121 (2005) 63–72.
[42] M. Bruce, A. Chree, I. McConnell, J. Foster, G. Pearson, H. Fraser,
Transmission of bovine spongiform encephalopathy and scrapie to mice:
689R. Morales et al. / Biochimica et Biophysica Acta 1772 (2007) 681–691strain variation and the species barrier, Philos. Trans. R. Soc. Lond., B
Biol. Sci. 343 (1994) 405–411.
[43] H. Fraser, M.E. Bruce, A. Chree, I. McConnell, G.A. Wells, Transmission
of bovine spongiform encephalopathy and scrapie to mice, J. Gen. Virol.
73 (1992) 1891–1897.
[44] T. Muramoto, T. Kitamoto, J. Tateishi, I. Goto, Successful transmission of
Creutzfeldt–Jakob disease from human to mouse verified by prion
protein accumulation in mouse brains, Brain Res. 599 (1992) 309–316.
[45] A.F. Hill, J. Collinge, Prion strains and species barriers, Contrib.
Microbiol. 11 (2004) 33–49.
[46] D. Peretz, R.A. Williamson, G. Legname, Y. Matsunaga, J. Vergara, D.R.
Burton, S.J. DeArmond, S.B. Prusiner, M.R. Scott, A change in the
conformation of prions accompanies the emergence of a new prion strain,
Neuron 34 (2002) 921–932.
[47] R.A. Moore, I. Vorberg, S.A. Priola, Species barriers in prion diseases–
brief review, Arch. Virol., Suppl. (2005) 187–202.
[48] D.L. Vanik, K.A. Surewicz, W.K. Surewicz, Molecular basis of barriers
for interspecies transmissibility of mammalian prions, Mol. Cell 14
(2004) 139–145.
[49] S.B. Prusiner, M. Scott, D. Foster, K.M. Pan, D. Groth, C. Mirenda, M.
Torchia, S.L. Yang, D. Serban, G.A. Carlson, Transgenetic studies
implicate interactions between homologous PrP isoforms in scrapie prion
replication, Cell 63 (1990) 673–686.
[50] S.G. Chen, P. Gambetti, A journey through the species barrier, Neuron 34
(2002) 854–856.
[51] P.G. Smith, R. Bradley, Bovine spongiform encephalopathy (BSE) and its
epidemiology, Br. Med. Bull. 66 (2003) 185–198.
[52] J.G. Collee, R. Bradley, BSE: a decade on–Part I, Lancet 349 (1997)
636–641.
[53] J.G. Collee, R. Bradley, BSE: a decade on–Part 2, Lancet 349 (1997)
715–721.
[54] A.F. Hill, M. Desbruslais, S. Joiner, K.C. Sidle, I. Gowland, J. Collinge,
L.J. Doey, P. Lantos, The same prion strain causes vCJD and BSE. Nature
389 (1997) 448–50, 526.
[55] J. Collinge, Variant Creutzfeldt–Jakob disease, Lancet 354 (1999)
317–323.
[56] A. Gombojav, I. Shimauchi, M. Horiuchi, N. Ishiguro, M. Shinagawa, T.
Kitamoto, I. Miyoshi, S. Mohri, M. Takata, Susceptibility of transgenic
mice expressing chimeric sheep, bovine and human PrP genes to sheep
scrapie, J. Vet. Med. Sci. 65 (2003) 341–347.
[57] J.K. Kirkwood, A.A. Cunningham, Epidemiological observations on
spongiform encephalopathies in captive wild animals in the British Isles,
Vet. Rec. 135 (1994) 296–303.
[58] G.R. Pearson, J.M. Wyatt, T.J. Gruffydd-Jones, J. Hope, A. Chong, R.J.
Higgins, A.C. Scott, G.A. Wells, Feline spongiform encephalopathy:
fibril and PrP studies, Vet. Rec. 131 (1992) 307–310.
[59] D.M. Taylor, S.L. Woodgate, Bovine spongiform encephalopathy: the
causal role of ruminant-derived protein in cattle diets, Rev. Sci. Tech. 16
(1997) 187–198.
[60] N. Bons, N. Mestre-Frances, P. Belli, F. Cathala, D.C. Gajdusek, P.
Brown, Natural and experimental oral infection of nonhuman primates by
bovine spongiform encephalopathy agents, Proc. Natl. Acad. Sci. U. S. A.
96 (1999) 4046–4051.
[61] S.J. Ryder, S.A. Hawkins, M. Dawson, G.A. Wells, The neuropathology
of experimental bovine spongiform encephalopathy in the pig, J. Comp.
Pathol. 122 (2000) 131–143.
[62] G.A. Wells, S.A. Hawkins, A.R. Austin, S.J. Ryder, S.H. Done, R.B.
Green, I. Dexter, M. Dawson, R.H. Kimberlin, Studies of the
transmissibility of the agent of bovine spongiform encephalopathy to
pigs, J. Gen. Virol. 84 (2003) 1021–1031.
[63] J. Castilla, A. Gutierrez-Adan, A. Brun, D. Doyle, B. Pintado, M.A.
Ramirez, F.J. Salguero, B. Parra, S.S. Diaz, J.M. Sanchez-Vizcaino, M.
Rogers, J.M. Torres, Subclinical bovine spongiform encephalopathy
infection in transgenic mice expressing porcine prion protein, J. Neurosci.
24 (2004) 5063–5069.
[64] J.D. Foster, J. Hope, H. Fraser, Transmission of bovine spongiform
encephalopathy to sheep and goats, Vet. Rec. 133 (1993) 339–341.
[65] M.J. Stack, M.J. Chaplin, J. Clark, Differentiation of prion proteinglycoforms from naturally occurring sheep scrapie, sheep-passaged
scrapie strains (CH1641 and SSBP1), bovine spongiform encephalopathy
(BSE) cases and Romney and Cheviot breed sheep experimentally
inoculated with BSE using two monoclonal antibodies, Acta Neuro-
pathol. (Berl) 104 (2002) 279–286.
[66] J.W. Wilesmith, G.A. Wells, M.P. Cranwell, J.B. Ryan, Bovine spongi-
form encephalopathy: epidemiological studies, Vet. Rec. 123 (1988)
638–644.
[67] J.W. Wilesmith, J.B. Ryan, M.J. Atkinson, Bovine spongiform
encephalopathy: epidemiological studies on the origin, Vet. Rec. 128
(1991) 199–203.
[68] C.J. Sigurdson, M.W. Miller, Other animal prion diseases, Br. Med. Bull.
66 (2003) 199–212.
[69] E.S. Williams, Chronic wasting disease, Vet. Pathol. 42 (2005) 530–549.
[70] E.D. Belay, P. Gambetti, L.B. Schonberger, P. Parchi, D.R. Lyon, S.
Capellari, J.H. McQuiston, K. Bradley, G. Dowdle, J.M. Crutcher, C.R.
Nichols, Creutzfeldt–Jakob disease in unusually young patients who
consumed venison, Arch. Neurol. 58 (2001) 1673–1678.
[71] R.F. Marsh, A.E. Kincaid, R.A. Bessen, J.C. Bartz, Interspecies
transmission of chronic wasting disease prions to squirrel monkeys
(Saimiri sciureus), J. Virol. 79 (2005) 13794–13796.
[72] A.N. Hamir, R.C. Cutlip, J.M. Miller, E.S. Williams, M.J. Stack, M.W.
Miller, K.I. O'Rourke, M.J. Chaplin, Preliminary findings on the
experimental transmission of chronic wasting disease agent of mule
deer to cattle, J. Vet. Diagn. Invest. 13 (2001) 91–96.
[73] A.N. Hamir, R.A. Kunkle, R.C. Cutlip, J.M. Miller, K.I. O'Rourke,
E.S. Williams, M.W. Miller, M.J. Stack, M.J. Chaplin, J.A. Richt,
Experimental transmission of chronic wasting disease agent from mule
deer to cattle by the intracerebral route, J. Vet. Diagn. Invest. 17 (2005)
276–281.
[74] A.N. Hamir, J.M. Miller, R.C. Cutlip, M.J. Stack, M.J. Chaplin, A.L.
Jenny, E.S. Williams, Experimental inoculation of scrapie and chronic
wasting disease agents in raccoons (Procyon lotor), Vet. Rec. 153 (2003)
121–123.
[75] Q. Kong, S. Huang, W. Zou, D. Vanegas, M. Wang, D. Wu, J. Yuan, M.
Zheng, H. Bai, H. Deng, K. Chen, A.L. Jenny, K. O'Rourke, E.D. Belay,
L.B. Schonberger, R.B. Petersen, M.S. Sy, S.G. Chen, P. Gambetti,
Chronic wasting disease of elk: transmissibility to humans examined by
transgenic mouse models, J. Neurosci. 25 (2005) 7944–7949.
[76] C.I. Lasmezas, J.P. Deslys, O. Robain, A. Jaegly, V. Beringue, J.M.
Peyrin, J.G. Fournier, J.J. Hauw, J. Rossier, D. Dormont, Transmission of
the BSE agent to mice in the absence of detectable abnormal prion
protein, Science 275 (1997) 402–405.
[77] E.E. Manuelidis, E.J. Gorgacz, L. Manuelidis, Transmission of
Creutzfeldt–Jakob disease with scrapie-like syndromes to mice, Nature
271 (1978) 778–779.
[78] J. Tateishi, Y. Sato, H. Nagara, J.W. Boellaard, Experimental transmission
of human subacute spongiform encephalopathy to small rodents. IV.
Positive transmission from a typical case of Gerstmann–Straussler–
Scheinker's disease, Acta Neuropathol. (Berl) 64 (1984) 85–88.
[79] R.J. Kascsak, R. Rubenstein, P.A. Merz, R.I. Carp, N.K. Robakis, H.M.
Wisniewski, H. Diringer, Immunological comparison of scrapie-asso-
ciated fibrils isolated from animals infected with four different scrapie
strains, J. Virol. 59 (1986) 676–683.
[80] R. Rubenstein, P.A. Merz, R.J. Kascsak, C.L. Scalici, M.C. Papini, R.I.
Carp, R.H. Kimberlin, Scrapie-infected spleens: analysis of infectivity,
scrapie-associated fibrils, and protease-resistant proteins, J. Infect. Dis.
164 (1991) 29–35.
[81] R.J. Kascsak, R. Rubenstein, P.A. Merz, R.I. Carp, H.M. Wisniewski, H.
Diringer, Biochemical differences among scrapie-associated fibrils
support the biological diversity of scrapie agents, J. Gen. Virol. 66
(1985) 1715–1722.
[82] G. Legname, H.O. Nguyen, I.V. Baskakov, F.E. Cohen, S.J. DeArmond,
S.B. Prusiner, Strain-specified characteristics of mouse synthetic prions,
Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2168–2173.
[83] T. Baron, C. Crozet, A.G. Biacabe, S. Philippe, J. Verchere, A. Bencsik, J.
Y. Madec, D. Calavas, J. Samarut, Molecular analysis of the protease-
resistant prion protein in scrapie and bovine spongiform encephalopathy
690 R. Morales et al. / Biochimica et Biophysica Acta 1772 (2007) 681–691transmitted to ovine transgenic and wild-type mice, J. Virol. 78 (2004)
6243–6251.
[84] A.M. Thackray, M.A. Klein, R. Bujdoso, Subclinical prion disease
induced by oral inoculation, J. Virol. 77 (2003) 7991–7998.
[85] J. Tateishi, M. Ohta, M. Koga, Y. Sato, Y. Kuroiwa, Transmission of
chronic spongiform encephalopathy with kuru plaques from humans to
small rodents, Ann. Neurol. 5 (1979) 581–584.
[86] J. Collinge, F. Owen, M. Poulter, M. Leach, T.J. Crow, M.N. Rossor, J.
Hardy, M.J. Mullan, I. Janota, P.L. Lantos, Prion dementia without
characteristic pathology, Lancet 336 (1990) 7–9.
[87] R. Medori, P. Montagna, H.J. Tritschler, A. LeBlanc, P. Cortelli, P.
Tinuper, E. Lugaresi, P. Gambetti, Fatal familial insomnia: a second
kindred with mutation of prion protein gene at codon 178, Neurology 42
(1992) 669–670.
[88] S.E. Lloyd, S.R. Thompson, J.A. Beck, J.M. Linehan, J.D. Wadsworth,
S. Brandner, J. Collinge, E.M. Fisher, Identification and characteriza-
tion of a novel mouse prion gene allele, Mamm. Genome 15 (2004)
383–389.
[89] R.A. Bessen, R.F. Marsh, Distinct PrP properties suggest the molecular
basis of strain variation in transmissible mink encephalopathy, J. Virol. 68
(1994) 7859–7868.
[90] R.A. Bessen, D.A. Kocisko, G.J. Raymond, S. Nandan, P.T. Lansbury, B.
Caughey, Non-genetic propagation of strain-specific properties of scrapie
prion protein, Nature 375 (1995) 698–700.
[91] A.G. Dickinson, V.M. Meikle, Host-genotype and agent effects in scrapie
incubation: change in allelic interaction with different strains of agent,
Mol. Gen. Genet. 112 (1971) 73–79.
[92] R.I. Carp, R.C. Moretz, M. Natelli, A.G. Dickinson, Genetic control of
scrapie: incubation period and plaque formation in I mice, J. Gen. Virol.
68 (1987) 401–407.
[93] G.A. Carlson, D.T. Kingsbury, P.A. Goodman, S. Coleman, S.T.
Marshall, S. DeArmond, D. Westaway, S.B. Prusiner, Linkage of prion
protein and scrapie incubation time genes, Cell 46 (1986) 503–511.
[94] N. Hunter, J.C. Dann, A.D. Bennett, R.A. Somerville, I. McConnell, J.
Hope, Are Sinc and the PrP gene congruent? Evidence from PrP gene
analysis in Sinc congenic mice, J. Gen. Virol. 73 (1992) 2751–2755.
[95] S.L. Benestad, P. Sarradin, B. Thu, J. Schonheit, M.A. Tranulis, B.
Bratberg, Cases of scrapie with unusual features in Norway and
designation of a new type, Nor98, Vet. Rec. 153 (2003) 202–208.
[96] J.D. Foster, D. Parnham, A. Chong, W. Goldmann, N. Hunter, Clinical
signs, histopathology and genetics of experimental transmission of
BSE and natural scrapie to sheep and goats, Vet. Rec. 148 (2001)
165–171.
[97] M.A. Tranulis, A. Osland, B. Bratberg, M.J. Ulvund, Prion protein gene
polymorphisms in sheep with natural scrapie and healthy controls in
Norway, J. Gen. Virol. 80 (1999) 1073–1077.
[98] J. Collinge, M.S. Palmer, A.J. Dryden, Genetic predisposition to
iatrogenic Creutzfeldt–Jakob disease, Lancet 337 (1991) 1441–1442.
[99] M.S. Palmer, A.J. Dryden, J.T. Hughes, J. Collinge, Homozygous prion
protein genotype predisposes to sporadic Creutzfeldt–Jakob disease,
Nature 352 (1991) 340–342.
[100] H.S. Lee, P. Brown, L. Cervenakova, R.M. Garruto, M.P. Alpers, D.C.
Gajdusek, L.G. Goldfarb, Increased susceptibility to Kuru of carriers of
the PRNP 129 methionine/methionine genotype, J. Infect. Dis. 183
(2001) 192–196.
[101] S. Mead, M.P. Stumpf, J. Whitfield, J.A. Beck, M. Poulter, T. Campbell,
J.B. Uphill, D. Goldstein, M. Alpers, E.M. Fisher, J. Collinge, Balancing
selection at the prion protein gene consistent with prehistoric kurulike
epidemics, Science 300 (2003) 640–643.
[102] J.J. Hauw, V. Sazdovitch, J.L. Laplanche, K. Peoc'h, N. Kopp, J.
Kemeny, N. Privat, N. Delasnerie-Laupretre, J.P. Brandel, J.P. Deslys, D.
Dormont, A. Alperovitch, Neuropathologic variants of sporadic Creutz-
feldt–Jakob disease and codon 129 of PrP gene, Neurology 54 (2000)
1641–1646.
[103] P. Parchi, A. Giese, S. Capellari, P. Brown, W. Schulz-Schaeffer, O.
Windl, I. Zerr, H. Budka, N. Kopp, P. Piccardo, S. Poser, A. Rojiani, N.
Streichemberger, J. Julien, C. Vital, B. Ghetti, P. Gambetti, H.
Kretzschmar, Classification of sporadic Creutzfeldt–Jakob diseasebased on molecular and phenotypic analysis of 300 subjects, Ann.
Neurol. 46 (1999) 224–233.
[104] L.G. Goldfarb, R.B. Petersen, M. Tabaton, P. Brown, A.C. LeBlanc, P.
Montagna, P. Cortelli, J. Julien, C. Vital, W.W. Pendelbury, Fatal familial
insomnia and familial Creutzfeldt–Jakob disease: disease phenotype
determined by a DNA polymorphism, Science 258 (1992) 806–808.
[105] A.F. Hill, S. Joiner, J.D. Wadsworth, K.C. Sidle, J.E. Bell, H. Budka, J.W.
Ironside, J. Collinge, Molecular classification of sporadic Creutzfeldt–
Jakob disease, Brain 126 (2003) 1333–1346.
[106] J.P. Brandel, M. Preece, P. Brown, E. Croes, J.L. Laplanche, Y. Agid, R.
Will, A. Alperovitch, Distribution of codon 129 genotype in human
growth hormone-treated CJD patients in France and the UK, Lancet 362
(2003) 128–130.
[107] M.T. Bishop, P. Hart, L. Aitchison, H.N. Baybutt, C. Plinston, V.
Thomson, N.L. Tuzi, M.W. Head, J.W. Ironside, R.G. Will, J.C. Manson,
Predicting susceptibility and incubation time of human-to-human
transmission of vCJD, Lancet Neurol. 5 (2006) 393–398.
[108] A. Aguzzi, Prion diseases of humans and farm animals: epidemiology,
genetics, and pathogenesis, J. Neurochem. 97 (2006) 1726–1739.
[109] J. Collinge, J. Beck, T. Campbell, K. Estibeiro, R.G. Will, Prion protein
gene analysis in new variant cases of Creutzfeldt–Jakob disease, Lancet
348 (1996) 56.
[110] M. Glatzel, K. Stoeck, H. Seeger, T. Luhrs, A. Aguzzi, Human prion
diseases: molecular and clinical aspects, Arch. Neurol. 62 (2005)
545–552.
[111] P. Gambetti, Q. Kong, W. Zou, P. Parchi, S.G. Chen, Sporadic and
familial CJD: classification and characterisation, Br. Med. Bull. 66 (2003)
213–239.
[112] P. Parchi, W. Zou, W. Wang, P. Brown, S. Capellari, B. Ghetti, N. Kopp,
W.J. Schulz-Schaeffer, H.A. Kretzschmar, M.W. Head, J.W. Ironside, P.
Gambetti, S.G. Chen, Genetic influence on the structural variations of the
abnormal prion protein, Proc. Natl. Acad. Sci. U. S. A 97 (2000)
10168–10172.
[113] G. Schoch, H. Seeger, J. Bogousslavsky, M. Tolnay, R.C. Janzer, A.
Aguzzi, M. Glatzel, Analysis of prion strains by PrP(Sc) profiling in
sporadic Creutzfeldt–Jakob disease, PLoS Med. 3 (2005) e14.
[114] G. Puoti, G. Rossi, G. Giaccone, T. Awan, P.M. Lievens, C.A. Defanti, F.
Tagliavini, O. Bugiani, Polymorphism at codon 129 of PRNP affects the
phenotypic expression of Creutzfeldt–Jakob disease linked to E200K
mutation, Ann. Neurol. 48 (2000) 269–270.
[115] M. Bianca, S. Bianca, I. Vecchio, R. Raffaele, C. Ingegnosi, F. Nicoletti,
Gerstmann–Straussler–Scheinker disease with P102L-V129 mutation: a
case with psychiatric manifestations at onset, Ann. Genet. 46 (2003)
467–469.
[116] P. Montagna, P. Cortelli, P. Avoni, P. Tinuper, G. Plazzi, R. Gallassi, F.
Portaluppi, J. Julien, C. Vital, M.B. Delisle, P. Gambetti, E. Lugaresi,
Clinical features of fatal familial insomnia: phenotypic variability in
relation to a polymorphism at codon 129 of the prion protein gene, Brain
Pathol. 8 (1998) 515–520.
[117] R.B. Petersen, L.G. Goldfarb, M. Tabaton, P. Brown, L. Monari, P.
Cortelli, P. Montagna, L. Autilio-Gambetti, D.C. Gajdusek, E. Lugaresi,
A novel mechanism of phenotypic heterogeneity demonstrated by the
effect of a polymorphism on a pathogenic mutation in the PRNP (prion
protein gene), Mol. Neurobiol. 8 (1994) 99–103.
[118] P. Cortelli, P. Gambetti, P. Montagna, E. Lugaresi, Fatal familial
insomnia: clinical features and molecular genetics, J. Sleep Res. 8
(Suppl. 1) (1999) 23–29.
[119] J.A. Hainfellner, P. Parchi, T. Kitamoto, C. Jarius, P. Gambetti, H. Budka,
A novel phenotype in familial Creutzfeldt–Jakob disease: prion protein
gene E200K mutation coupled with valine at codon 129 and type 2
protease-resistant prion protein, Ann. Neurol. 45 (1999) 812–816.
[120] S. Liemann, R. Glockshuber, Influence of amino acid substitutions
related to inherited human prion diseases on the thermodynamic stability
of the cellular prion protein, Biochemistry 38 (1999) 3258–3267.
[121] R. Zahn, A. Liu, T. Luhrs, R. Riek, C. von Schroetter, G.F. Lopez, M.
Billeter, L. Calzolai, G. Wider, K. Wuthrich, NMR solution structure of
the human prion protein, Proc. Natl. Acad. Sci. U. S. A. 97 (2000)
145–150.
691R. Morales et al. / Biochimica et Biophysica Acta 1772 (2007) 681–691[122] B.S. Wong, C. Clive, S.J. Haswell, R.A. Williamson, D.R. Burton, P.
Gambetti, M.S. Sy, I.M. Jones, D.R. Brown, Copper has differential
effect on prion protein with polymorphism of position 129, Biochem.
Biophys. Res. Commun. 269 (2000) 726–731.
[123] C. Petchanikow, G.P. Saborio, L. Anderes, M.J. Frossard, M.I. Olmedo,
C. Soto, Biochemical and structural studies of the prion protein
polymorphism, FEBS Lett. 509 (2001) 451–456.
[124] E.R. Mulcahy, R.A. Bessen, Strain-specific kinetics of prion protein
formation in vitro and in vivo, J. Biol. Chem. 279 (2004)
1643–1649.
[125] G. Puoti, G. Giaccone, G. Rossi, B. Canciani, O. Bugiani, F. Tagliavini,
Sporadic Creutzfeldt–Jakob disease: co-occurrence of different types of
PrP(Sc) in the same brain, Neurology 53 (1999) 2173–2176.
[126] M. Pocchiari, M. Puopolo, E.A. Croes, H. Budka, E. Gelpi, S. Collins,
V. Lewis, T. Sutcliffe, A. Guilivi, N. Delasnerie-Laupretre, J.P. Brandel,
A. Alperovitch, I. Zerr, S. Poser, H.A. Kretzschmar, A. Ladogana, I.
Rietvald, E. Mitrova, P. Martinez-Martin, J. Pedro-Cuesta, M. Glatzel,
A. Aguzzi, S. Cooper, J. Mackenzie, C.M. van Duijn, R.G. Will,
Predictors of survival in sporadic Creutzfeldt–Jakob disease and other
human transmissible spongiform encephalopathies, Brain 127 (2004)
2348–2359.
[127] P. Brown, P. Rodgers-Johnson, F. Cathala, C.J. Gibbs Jr., D.C. Gajdusek,
Creutzfeldt–Jakob disease of long duration: clinicopathological char-acteristics, transmissibility, and differential diagnosis, Ann. Neurol. 16
(1984) 295–304.
[128] A.G. Dickinson, H. Fraser, G.W. Outram, Scrapie incubation time can
exceed natural lifespan, Nature 256 (1975) 732–733.
[129] R.H. Kimberlin, C.A. Walker, Competition between strains of scrapie
depends on the blocking agent being infectious, Intervirology 23 (1985)
74–81.
[130] J.C. Bartz, J.M. Aiken, R.A. Bessen, Delay in onset of prion disease for
the HY strain of transmissible mink encephalopathy as a result of prior
peripheral inoculation with the replication-deficient DY strain, J. Gen.
Virol. 85 (2004) 265–273.
[131] C. Weissmann, A. Aguzzi, Approaches to therapy of prion diseases,
Annu. Rev. Med. 56 (2005) 321–344.
[132] C. Soto, R.J. Kascsak, G.P. Saborio, P. Aucouturier, T. Wisniewski, F.
Prelli, R. Kascsak, E. Mendez, D.A. Harris, J. Ironside, F. Tagliavini, R.
I. Carp, B. Frangione, Reversion of prion protein conformational
changes by synthetic beta-sheet breaker peptides, Lancet 355 (2000)
192–197.
[133] D. Peretz, R.A. Williamson, K. Kaneko, J. Vergara, E. Leclerc, G.
Schmitt-Ulms, I.R. Mehlhorn, G. Legname, M.R. Wormald, P.M. Rudd,
R.A. Dwek, D.R. Burton, S.B. Prusiner, Antibodies inhibit prion
propagation and clear cell cultures of prion infectivity, Nature 412
(2001) 739–743.
